Use of Anticholinergic Drugs in People Referred to an Urban Memory Clinic Service Setting

Sawhney, Ina

doi:10.46998/ijcmcr.2021.12.000293

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Living older does not necessarily mean having a healthy life [2]. Thus, sensory changes, physical and mental frailty, cardiovascular diseases and diabetes, osteoarthritis, osteoporosis, and falls appear to be frequent in older people and are more pronounced above the age of 85 years [3]. These, alongside accompanying polypharmacy, especially anticholinergic drugs [4], all have a negative impact on activities of daily living [5], leading to many older people requiring support from formal and informal carers [6].…”

Section: Introductionmentioning

confidence: 99%

Hyperbaric oxygen therapy—a new hope for Alzheimer’s patients: a case report and literature review

Mukaetova-Ladinska,

Steptoe,

Critchfield

et al. 2023

Explor Neuroprot Ther

View full text Add to dashboard Cite

The currently available pharmacological anti-dementia treatments provide only temporary and limited benefits. Not surprisingly, patients and professionals increasingly explore non-pharmacological interventions that may alleviate dementia symptoms. Among these interventions is hyperbaric oxygen therapy (HBOT). A brief review is presented on HBOT use in medicine, with its mode of action in dementia, specifically Alzheimer’s disease, as well as a case report of self-initiated HBOT in a 63-year-old man with a clinical diagnosis of probable Alzheimer’s disease. He had over 400 HBOT sessions [2–3 times weekly, with a duration of 30–50 min, in a multi-place hyperbaric chamber at 2 atmospheres absolute (ATA)] over 7 years and use of donepezil (10 mg daily) for the last 3 years when formally diagnosed by the National Health Service (NHS) Memory Service. The patient’s longitudinal neurocognitive and neuroradiological evidence over 7 years of follow-up remained stable (with no major cognitive decline and no behavioral changes) when compared to his initial presentation when diagnosed by the private health provider. His driving remains unimpaired, and he continues to be independent. This highlights the potential HBOT benefits including those on visuospatial ability and activities of daily living in people with Alzheimer’s disease. This case report argues for more extensive research into the clinical effects of HBOT in Alzheimer’s disease. Discussion of HBOT use is along with the latest advances in anti-amyloid immunotherapy for Alzheimer’s disease, as well as HBOT augmentation of current and novel dementia drug delivery via nanotechnology.

show abstract